Sec. 491.052. PATIENT ELIGIBILITY. A patient is eligible to access an individualized investigational treatment under this chapter if: (1) the patient: (A) has a life-threatening illness or severely debilitating illness; (B) has considered all other treatment options currently approved by the United States Food and Drug Administration; and (C) has given written informed consent for access to the treatment; and (2) the patient's physician: (A) attests to the patient's life-threatening illness or severely debilitating illness and the patient's eligibility under this section; and (B) recommends the treatment for the patient based on analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products such as enzymes and other types of proteins, or metabolites. Added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1, eff. September 1, 2025.
Patient Eligibility
Tex. Health and Safety Code § 491.052 (as added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984)), under Access To Individualized Investigational Treatments For Patients With Life-Threatening Or Severely Debilitating Illnesses.
Tex. Health and Safety Code § 491.052 (as added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984))